Affordable Access

deepdyve-link
Publisher Website

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence.

Authors
  • Kesarwani, Meenu1
  • Kincaid, Zachary1
  • Azam, Mohammad2
  • 1 Cancer Blood Disease Institute, Divisions of Experimental Hematology and Cancer Pathology, Cincinnati Children's Hospital Medical Center.
  • 2 Cancer Blood Disease Institute, Divisions of Experimental Hematology and Cancer Pathology, Cincinnati Children's Hospital Medical Center; [email protected]
Type
Published Article
Journal
Journal of Visualized Experiments
Publisher
MyJoVE Corporation
Publication Date
Jan 07, 2019
Issue
143
Identifiers
DOI: 10.3791/58194
PMID: 30663656
Source
Medline
Language
English
License
Unknown

Abstract

The demonstration of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) has heralded a new era in cancer therapeutics. However, a small population of cells does not respond to TKI treatment, resulting in minimal residual disease (MRD); even the most potent TKIs fail to eradicate these cells. These MRD cells serve as a reservoir to develop resistance to therapy. Why TKI treatment is ineffective against MRD cells is not known. Growth factor signaling is implicated in supporting the survival of MRD cells during TKI treatment, but a mechanistic understanding is lacking. Recent studies demonstrated that an elevated c-Fos and Dusp1 expression as a result of convergent oncogenic and growth factor signaling in MRD cells mediate TKI resistance. The genetic and chemical inhibition of c-Fos and Dusp1 renders CML exquisitely sensitive to TKIs and cures CML in both genetic and humanized mouse models. We identified these target genes using multiple microarrays from TKI-sensitive and -resistant cells. Here, we provide methods for target validation using in vitro and in vivo mouse models. These methods can easily be applied to any target for genetic validation and therapeutic development.

Report this publication

Statistics

Seen <100 times